SCHEMBL1361448

SCHEMBL1361448

C=CC(O)CC/C=C/CC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.38
CYP19A1 P11511 4/20 0.38
MAPT P10636 4/20 0.38
PPARG P37231 3/20 0.38
OXER1 Q8TDS5 3/20 0.38
RXRA P19793 2/20 0.38
FFAR1 O14842 2/20 0.38
F7 P08709 3/20 0.35
F3 P13726 3/20 0.35
PTGS1 P23219 3/20 0.35
KMT2A Q03164 2/20 0.35
PPARD Q03181 2/20 0.35
PPARA Q07869 2/20 0.35
ADORA3 P0DMS8 2/20 0.35
NR1I2 O75469 2/20 0.33
PTGS2 P35354 2/20 0.33
CYP3A4 P08684 2/20 0.33
ALOX15 P16050 2/20 0.33
HSD17B10 Q99714 2/20 0.33
TDP1 Q9NUW8 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1361451 1.00 ALDH1A1 (0.38) ALDH1A1CYP19A1MAPTPPARGOXER1
SCHEMBL31719711 0.82 PPARG (0.30) PPARGPPARDPPARA
SCHEMBL1834214 0.82 PPARG (0.30) PPARGPPARDPPARA
SCHEMBL15796546 0.82 PPARG (0.30) PPARGPPARDPPARA
SCHEMBL869791 0.81
SCHEMBL31275238 0.81
SCHEMBL869790 0.81
SCHEMBL7770802 0.81 ABCG2 (0.47) CYP19A1MAPTPPARGFFAR1F7
SCHEMBL9086095 0.79 PPARG (0.50) CYP19A1MAPTPPARGFFAR1F7
SCHEMBL23531389 0.79 FPR2 (0.40) ALDH1A1CYP19A1MAPTPPARGOXER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2845896-B1 A process of using a consumer product for treating fabric PROCTER & GAMBLE (US) 2025-03-26 EP claimed
US-20240010954-A1 LAUNDRY DETERGENT COMPOSITION CONTAINING GRAFT COPOLYMER AND BENEFIT AGENT THE PROCTER & GAMBLE COMPANY 2024-01-11 US claimed
EP-3191191-B1 BENEFIT AGENT CONTAINING DELIVERY PARTICLE BASED ON STYRENE MALEIC ANHYDRIDE COPOLYMER PROCTER & GAMBLE (US) 2022-04-13 EP claimed
EP-3052551-B1 BENEFIT AGENT CONTAINING DELIVERY PARTICLE ENCAPSYS LLC (US) 2021-12-01 EP claimed
US-10336966-B2 Fragrance compositions and uses thereof THE PROCTER & GAMBLE COMPANY (US) 2019-07-02 US claimed
US-9969961-B2 Benefit agent containing delivery particle THE PROCTER & GAMBLE COMPANY (US) 2018-05-15 US claimed
US-9814661-B2 Fragrance compositions THE PROCTER & GAMBLE COMPANY (US) 2017-11-14 US claimed
EP-2961374-B1 FRAGRANCE COMPOSITIONS PROCTER & GAMBLE (US) 2017-01-25 EP claimed
EP-2961374-A1 FRAGRANCE COMPOSITIONS The Procter & Gamble Company (US) 2016-01-06 EP claimed
US-20150164764-A1 Fragrance Compositions THE PROCTER & GAMBLE COMPANY 2015-06-18 US claimed
WO-2015089246-A1 FRAGRANCE COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2015-06-18 WO claimed
US-20150099680-A1 BENEFIT AGENT CONTAINING DELIVERY PARTICLE THE PROCTER & GAMBLE COMPANY 2015-04-09 US claimed
US-8940395-B2 Benefit agent containing delivery particle THE PROCTER & GAMBLE COMPANY (US) 2015-01-27 US claimed
US-20140357547-A1 PROCESS FOR THE PREPARATION OF METHOXYMELONAL GIVAUDAN S.A. (CH) 2014-12-04 US claimed
US-8754028-B2 Perfume systems THE PROCTER & GAMBLE COMPANY (US) 2014-06-17 US claimed
EP-2094828-B1 BENEFIT AGENT CONTAINING DELIVERY PARTICLE APPLETON PAPER INC (US) 2013-01-02 EP claimed
US-8067355-B2 Benefit agent containing delivery particles APPLETON PAPERS INC. (US) 2011-11-29 US claimed
US-20100261629-A1 Benefit agent containing delivery particles APPLETON PAPERS INC. (US) 2010-10-14 US claimed
US-20100152083-A1 Perfume Systems PROCTER & GAMBLE COMPANY, THE 2010-06-17 US claimed
US-20080118568-A1 Benefit agent containing delivery particle PROCTER & GAMBLE COMPANY, THE 2008-05-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357547-A1 PROCESS FOR THE PREPARATION OF METHOXYMELONAL MSMO1, CYP17A1, CYP51A1 ALDH1A1 736/4885CYP19A1 11/4885MAPT 1471/4885
US-20150164764-A1 Fragrance Compositions OGG1, ALKBH5, MYB ALDH1A1 1367/4885CYP19A1 439/4885MAPT 725/4885
US-10336966-B2 Fragrance compositions and uses thereof CUTA, DPM1, PLIN5 ALDH1A1 1263/4885CYP19A1 222/4885MAPT 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.